About two-thirds of genetic mutations in samples from primary tumors of kidney cancer patients were different from one another, even if they were taken from the same tumor, a British study revealed. Researchers also found even more genetic differentiation in biopsies of secondary tumors. The findings in the New England Journal of Medicine suggest that using samples from a primary tumor as a basis for treatment decisions may not be sufficient, researchers said.
Study finds "extraordinary" genetic diversity in tumors
SmartBrief Job Listings for Health Care
|Chief Financial Officer||
B. E. Smith
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|